Vice-president, Specialty Committee on Immunology of TCM, World Federation of Chinese Medicine Societies

Scientific advisory member, German Pharmaceutical Society (DPhG)

Executive council member, Natural Product Section, International Union of Basic and Clinical Pharmacology (IUPHAR)

Board of directors, German-Chinese Research foundation for Traditional Chinese Medicine

Board of directors, Good Practice in TCM Research Association

Member, Society for Medicinal Plant Research (GA)

Member, International Society of Ethnopharmacology

The vice chairman and the incoming chairman of the Respiratory Disease Branch of Hubei Medical Association, the chairman of the Youth Committee of the Respiratory Disease Branch of Hubei Medical Association, the deputy team leader and office director of the Medical Quality Control Center of Hubei Respiratory Medicine, the member of the Pulmonary Embolism and Pulmonary Vascular Disease Group of the Respiratory Branch of the Chinese Medical Association, and the member of the Asthma and Allergy Committee of the Chinese Medical Doctor Association. He studied for a bachelor's degree in clinical medicine at the former Tongji Medical University from 1987 to 1992, and studied for a doctorate in internal medicine respiratory medicine at Tongji Medical College of Huazhong University of Science and Technology from 1999 to 2002. He conducted postdoctoral research at the Medical College of Virginia in the United States from June 2005 to December 2006. He has been engaged in basic and clinical research related to pulmonary hypertension, chronic obstructive pulmonary disease and bronchial asthma. He has presided over four National Natural Science Foundation projects and participated in two key projects of the Ministry of Science and Technology as the sub-project leader. He has collaborated with colleagues to publish more than 120 papers in domestic and foreign academic journals, including more than 40 papers in SCI journals. The above work has won two internationally advanced scientific research results and one domestic leading level, and won the second prize of Wuhan Science and Technology Progress in Hubei Province, the second prize of Hubei Science and Technology Progress, the second prize of Ministry of Education Science and Technology Progress, and the first prize of Ministry of Education Science and Technology Progress.

Dr. Esteban Hernandez-Vargas is a researcher at the University of Idaho, USA. His work focuses on mathematical and computational modeling in cancer biology, immunology, and infectious diseases. He has a strong interdisciplinary background, integrating systems biology approaches to understand complex disease mechanisms. Dr. Hernandez-Vargas has authored numerous scientific publications and actively contributes to international research collaborations.

Dr. Jian Li is a researcher at the University of Bonn, Germany. His academic interests lie in biomedical sciences, with a focus on cancer biology, molecular mechanisms of disease, and translational medicine. Dr. Li is involved in interdisciplinary research projects and has contributed to several peer-reviewed publications. He is dedicated to advancing scientific understanding and fostering international academic collaboration.

Dr. Veronka Lukacs-Kornek is a researcher at the University of Bonn, Germany. Her work focuses on immunology and tumor microenvironment, with a special interest in the role of immune regulation in cancer development and therapy. She has published widely in peer-reviewed journals and contributes to collaborative international research efforts in translational oncology.

Member of the Tumor Microenvironment Committee of the Chinese Anti-Cancer Association;

Vice President of the Shandong Youth Medical Workers Association;

Chairman of the Tumor Stem Cells and Drug Resistance Committee of the Shandong Medical Education Association;

Vice Chairman of the Chemotherapy Pharmacology Committee of the Shandong Pharmacology Society;

Vice Chairman of the Gynecological Tumor Molecular Diagnosis and Treatment Branch of the Shandong Translational Medicine Society.

Has published more than 40 papers in Chinese and English as the first or corresponding author in important medical journals such as JAMA, Lancet sub-journals, and ANNALS OF ONCOLOGY. He presided over one joint fund of the National Natural Science Foundation of China and Germany Science Center, and presided over four provincial natural science foundation general projects. He is currently the chairman of the Sino-German Medical Evidence-Based Medicine Committee, the vice chairman of the Youth Committee of the Wuhan Medical Association Radiation Oncology Therapy Branch, and a member of the CSCO Smart Medical Committee.

Professor of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Director of the key laboratory of the National Health Commission

Director of the Biomedical Research Center and the Biobank

Chief scientist of the 13th Five-Year Plan "Developmental Programming and Its Metabolic Regulation" project

Deputy director of the Chinese Organ Transplant Immunology Committee, and vice chairman of the China Type 1 Diabetes Alliance

Professor, chief physician, doctor of medicine, postdoctoral fellow at the University of Maryland School of Medicine, doctoral supervisor, and co-supervisor of postdoctoral fellows. Deputy director of the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Selected into the National High-level Talent (Youth) Program. He has been engaged in clinical, scientific research and teaching work of various diseases of the blood system for a long time. He has rich clinical experience in the diagnosis and systemic treatment of various blood system diseases. He is particularly good at various types of allogeneic hematopoietic stem cell transplantation and cellular immunotherapy (CAR-T/CAR-NK) of blood system malignancies, including various types of acute and chronic leukemia, malignant lymphoma, multiple myeloma, etc. He also has rich experience in the treatment of acute and critical diseases of blood system diseases. He has presided over many National Natural Science Foundation and provincial and ministerial projects; he is a project review expert of the National Natural Science Foundation of China; as the main researcher, he has presided over many GCP registered clinical trials, researcher-initiated clinical studies and real-world clinical studies, and many clinical research results have been published in mainstream international academic journals. He is currently a member of the Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Group of the Hematology Tumor Committee of the Chinese Anti-Cancer Association, a member of the Hematopoietic Stem Cell Transplantation Committee of the China Primary Health Care Foundation, a member of the Cell Immunotherapy Committee of the Chinese Human Health Promotion Association, a member of the Hematology Youth Committee of the Chinese Medical Education Association, a member of the Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Group of the Hematology Tumor Committee of the Hubei Anti-Cancer Association, the deputy director of the Translational Medicine Research and Application Committee of the Hubei Extracellular Vesicle Society, and the deputy director of the Lymphoma Multidisciplinary Diagnosis and Treatment Committee of the Hubei Medical Biological Immunology Society. He was awarded the first Tongji Medical College Overseas Alumni Association-Zou Shengquan Youth Outstanding Clinical Research Award.

He has conducted research that has resulted in publications in international journals in the field of minimally invasive laparoscopic and robotic surgery for colorectal cancer. He has also published research on the role of surgery in the multimodal treatment of gastroenteropancreatic neuroendocrine tumors. He is actively involved in national and international educational meetings as a lecturer, particularly due to his experience in the field of neuroendocrine tumors.

He has been honored with several distinctions from professional ENT Societies including two Presidential Citations from the American Laryngological Associationfor his contributions made to the field of laryngology and the association. He has been appointed as the International Liaison for Corresponding Fellows of the American Laryngological Association. He is also a Fellowship External Examiner in Otorhinolaryngology at the Royal College of Surgeons in Ireland.

Dr. Giuliani is an expert General and Specialist Paediatric Surgeon treating neonates and children with surgical conditions from birth up to the age of 18 years.

His practice is based at the world-famous Great Ormond Street Hospital for Children in London and he sees children in the best paediatric private hospitals in Central London (The Portland Hospital, The Harley Street Clinic and Cromwell Hospital).

Deputy Head of Histological Diagnostics, Senior Physician

Dr. Hmadcha Abdelkrim is a senior researcher at the Biosanitary Research Institute (IIB-VIU) affiliated with the Valencian International University (VIU), Spain. With a solid background in biomedical sciences, Dr. Abdelkrim’s research primarily focuses on regenerative medicine, stem cell therapy, and immunological mechanisms in disease models, including cancer and metabolic disorders.

He has contributed significantly to the development and application of cellular and molecular techniques for translational medicine. His work integrates basic and clinical research, aiming to bridge the gap between laboratory findings and therapeutic approaches.

Dr. Sarah Allegra works as a Assistant Professor in the Laboratory of Clinical Pharmacology “Franco Ghezzo” at the S. Luigi Gonzaga University Hospital (Orbassano, Turin, Italy), a tertiary referral center in Italy for patients with adrenal diseases and endocrine tumors. Her research program is focused on gender pharmacology and the pharmacokinetics and pharmacogenetics of different drugs, such as iron chelating agents, antifungals, antiepileptics, glycopeptides, antiarrhythmics, and chemotherapies. Dr. Allegra obtained her master’s degree in cellular and molecular biology in 2013 at the University of Turin and her PhD title in Complex Systems for Life Sciences in 2018. Now, she is attending the Postgraduate Medical School in Gender Medicine. She has authored more than 60 peer-reviewed research papers, mostly focused on pharmacogenomics and personalized medicine. She is an active member of the Italian Society of Pharmacology. She is a collaborator with the “Centro Scienza Onlus” for public engagement activities.

Dr. Steven Brower is a faculty member at Hackensack Meridian School of Medicine, Nutley, New Jersey, USA. He is a surgical oncologist with extensive clinical and research experience in gastrointestinal and hepatobiliary cancers. Dr. Brower has contributed to numerous academic publications and is actively involved in cancer education, clinical trials, and multidisciplinary care initiatives.

Dr. Raphael Catane is affiliated with the Clinical Departments at the Faculty of Medicine, Tel Aviv University, Israel. He is a renowned medical oncologist with a strong background in cancer therapy, clinical trials, and translational oncology research. Dr. Catane has made significant contributions to cancer treatment development and has been actively involved in academic and clinical leadership throughout his career.

Dr. William Cho is a biomedical scientist at the Department of Clinical Oncology, Queen Elizabeth Hospital in Hong Kong. With a strong background in cancer biomarker discovery and translational research, Dr. Cho has published extensively in peer-reviewed journals. His research interests include genomics, proteomics, and liquid biopsy in oncology. He actively serves on editorial boards and is a frequent reviewer for international scientific journals.

Dr. Jonas Cicėnas is a molecular biologist with expertise in cancer signaling pathways, particularly MAP kinases. He is affiliated with the Life Sciences Center at Vilnius University and also contributes to the MAP Kinase Resource in Switzerland. His research focuses on understanding molecular mechanisms of cancer progression and therapeutic resistance. Dr. Cicėnas has authored numerous scientific publications and is actively involved in bioinformatics-driven oncology research.

Dr. Donato Colangelo is a researcher in pharmacology at the Department of Health Sciences, School of Medicine, Università del Piemonte Orientale in Novara, Italy. His work focuses on the pharmacological mechanisms underlying human diseases, with a particular interest in drug development and translational medicine. Dr. Colangelo contributes to academic teaching and collaborates on interdisciplinary research projects within the field of biomedical sciences.

Dr. Nils Cordes is a renowned expert in radiation oncology and tumor cell biology. He is affiliated with the Technische Universität Dresden Medical Faculty and OncoRay – the National Center for Radiation Research in Oncology, as well as the Helmholtz Center Dresden-Rossendorf. His research focuses on the molecular mechanisms of tumor resistance to radiotherapy, the tumor microenvironment, and the development of novel strategies to enhance cancer treatment efficacy. Dr. Cordes has published widely in high-impact journals and is recognized for his contributions to translational cancer research.

2003. Honorable mention. Examination to obtain the title of Doctor of Science in Molecular Biomedicine. ENMyH IPN.

2005. Lola and Igo Flisser-OUIS Award, UNAM. Best Doctoral Thesis in the area of Parasitology. Thesis "Stability of the mRNA of the multidrug resistance gene EhPgp5 and mechanisms that regulate polyadenylation in Entamoeba histolytica".

2008. XIX National Research Award. Glaxo Smith Klane-FUNSALUD Foundation. Work: "Identification of new genes involved in the genomic response to DNA damage in the human pathogen Entamoeba histolytica".

2009. Capital City Award: Heberto Castillo. Young Researcher Category. It is awarded by the Institute of Science and Technology of the Federal District, "for his contributions in the area of knowledge of amoebiasis and breast cancer."

2010. Bristol Award for Research in Advanced Breast Cancer. Work: "Identification of glyoxalase I as a possible tumor marker by proteomic analysis of breast carcinomas of Mexican women.

2016. National Award for Research in Science in Food Technology. Paper: "Overview of Breast Cancer Cell Methylation in Response to the Dietary Compound Resveratrol". Professional Category in Food Research and its Impact on Nutrition. Granted by CONACyT.

2017. National Oncology Award "Guillermo Montaño". Work: "The angiomiR miR-204 represses vasculogenic mimicry through inhibition of multiple VEGF/PI3K/AKT/FAK/SRC/RAF1 signaling pathways in breast cancer." Awarded by the Mexican Society of Oncology.

Dr. Valentina De Falco is a researcher at the Institute of Endocrinology and Experimental Oncology of the Italian National Research Council (CNR). Her work focuses on molecular mechanisms of cancer development and progression, particularly in endocrine-related tumors. She has contributed to numerous scientific publications and is actively involved in translational research aimed at improving cancer diagnosis and therapy.

Dr. Andrea Dell'amore is a researcher and clinician specializing in thoracic and cardiovascular surgery at the University of Padua, Italy. His work focuses on advanced surgical techniques, lung transplantation, and minimally invasive procedures. Dr. Dell'amore has contributed to numerous scientific publications and actively participates in academic and clinical research aimed at improving outcomes in cardiothoracic diseases.

The research interests of the applicant focus on two critical areas in cancer research: developing innovative therapeutic approaches to overcome resistance to cancer immunotherapy; and identifying genetic and epigenetic abnormalities in cancers and pre-cancers. He has authored 71 manuscripts in international journals, over half of them were published in journals with impact factor >10. He also served as an invited ad hoc reviewer and reviewed over 440 manuscripts for 131 international journals. Over the past two years, he has successfully secured more than 2.2 million SGD in research funding as the Principal Investigator (PI), and 3.5 million SGD as Co-Investigator and Collaborator. He also contributes as a Team Principal Investigator to a large CRP (Competitive Research Programme) grant from NRF. He was the recipient of the prestigious Lee Kuan Yew Postdoctoral Fellowship and the Year 2021 Gilead Research Scholars Award (Hematology and Oncology).

Author of 160 papers in national and international Journals.

Award winner: “2012 Corinne Farrell Best Paper in Skeletal Radiology”.

Winner in 2020 of the Blue Ribbon award for best article in the scientific journal "Orthopaedics".

Deputy Editor, European Journal of Orthopaedic Surgery and Traumatology.

Associate Editor: BMC Musculoskeletal Disorders; Current Oncology.

Deputy Director of Shanxi Bethune Hospital Cancer Center, Director of Thoracic Oncology Department, Doctor of Oncology
Outstanding Young Talent of Shanxi Province "Sanjin Talent" Support Program
Academic Positions:
Member of the International Association for the Study of Lung Cancer (IASLC);
Member of the Lung Cancer Group of the Oncology Branch of the Chinese Medical Association;
Member of the Standing Committee of the Melanoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO);
Member of the Melanoma Quality Control Committee of the National Cancer Center National Cancer Quality Control Center;
Director of the Shanxi Anti-Cancer Association;
Chairman of the Youth Committee of Tumor Metastasis Prevention and Treatment of the Shanxi Anti-Cancer Association;
Chairman of the Melanoma and Rare Target Tumor Committee of the Shanxi Gerontology and Geriatric Health Society;
Vice Chairman of the Youth Committee of Lung Cancer of the Shanxi Anti-Cancer Association; Vice Chairman of the Esophageal Cancer Committee;
Vice Chairman of the Tumor MDT Branch of the Shanxi Geriatrics Society;
Cancer plus》Journal Editorial Board Member
He has presided over 3 national horizontal projects and 5 provincial scientific research projects, and published more than 30 SCI papers; won 1 second prize for scientific and technological progress in Shanxi Province, presided over more than 20 national multicenter clinical studies as a sub-center PI, and initiated and presided over 3 IIT studies.

Dr. Giorgio Fiore is a neurosurgeon at the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. His clinical and research interests focus on brain and spinal tumors, minimally invasive neurosurgical techniques, and neuro-oncology. Dr. Fiore is actively involved in clinical practice, academic research, and multidisciplinary collaboration aimed at advancing neurosurgical care.

Pedro Fonte is Assistant Professor at the Faculty of Sciences and Technology, University of Algarve, Portugal. He is also an integrated member at Center of Marine Sciences (CCMAR), University of Algarve, Portugal and collaborator researcher at the Institute for Bioengineering and Biosciences, Instituto Superior Técnico, University of Lisbon, Portugal. He graduated in Pharmaceutical Sciences in 2010 and obtained his PhD in Pharmaceutical Sciences – Nanotechnologies specialty at the Faculty of Pharmacy, University of Porto, Portugal in collaboration with the University of Copenhagen, Denmark, in 2016. He also obtained a Master of Business Administration (MBA) at the Faculty of Economics and Business Management, Lusíada University, Portugal in 2012. His area of scientific activity is on the development of new drug delivery systems by means of colloidal carriers, structural characterization of proteins entrapped into micro- and nanocarriers, lyophilization of biopharmaceuticals, targeted and controlled delivery of drugs across biological barriers, solid state characterization of pharmaceuticals and drying of pharmaceuticals and biopharmaceuticals. He is also conducting research in the regenerative medicine field, focusing in wound healing, tissue regeneration and cell therapy. In his activity he is enrolled in the up-scale of pharmaceutical products and is involved in entrepreneurship activities.

Dr. Silvia De Francia is a researcher at the Department of Clinical and Biological Sciences, University of Turin, Italy. Her work focuses on pharmacogenetics, personalized medicine, and clinical pharmacology. She has contributed to numerous studies on the optimization of drug therapy based on genetic profiles and is actively involved in both academic research and teaching.

Dr. Dragos Eugen Georgescu is an Assistant Professor in the Department of Surgery at “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania. He obtained a Bachelor of Medicine at Faculty of Medicine - “Carol Davila” University of Medicine and Pharmacy- Medicine, Bucharest (Romania) - Licence Degree - 9.76. He earned Ph.D. in Medicine at “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, in 2019 - Doctor in Medicine, PhD Thesis: “Management of Neoadjuvant Therapy in Rectal Cancer”, coordinator Prof. Dr. Traian Pătrașcu.

He has a National Certificate in Hepato- Biliary-Pancreatic Surgery, in General Ultrasonography, in Level II Laparoscopic Surgery - Advanced Techniques and also in Oncologic Surgery. In 2023, he finished Second Residency in Plastic and Reconstructive Surgery. Is an Active Member of SRC (Romanian Society of Surgery) since 2012 and an Editorial Board Member of Romanian Journal of Surgery - CHIRURGIA (Bucur) since 2020, this being the most prestigious surgical journal in Romania. He is also a board member of other important journal, such as Frontiers In Oncology.

Assist. Prof. Dr. Dragos Eugen Georgescu is interested in fields of research like surgical oncology, hepatobiliopancreatic surgery, gynecologic oncology, laparoscopy, diabetic food surgery or difficult cholecystectomy. His present research focuses on searching predictive factors for response to radiochemotheraphy in both rectal and cervical cancer. He is also International Grant Member - DIAMARK Project code: PN-III-P4- PCE-2021-1344, Contract number: PCE 114/2022 -“Molecular markers for prediction of evolution and prognosis in diabetic foot management”

Dr. Arif Gulzar has obtained doctorate degree in Material Science and Engineering. His research focuses on cyclotron operation for the production of novel radioisotopes such as 68Ga etc and chelator free radiolabelling of nanoparticles for cancer theragnostic.

• Working Group Dermatological Oncology (ADO)
• Working Group Dermatological Histology (ADH)
• Working Group for Physical Diagnostics in Dermatology (ApDD)
• German Society for Dermatosurgery (DGDC)
• German Cancer Society (DKG)
• German - Israeli Dermatological Society
• Euro-Asian Association of Dermatovenerologists
• European Academy of Dermatology and Venereology
• International Confocal Working Group
• Women's Dermatologic Society
• Young Dermatovenereologists of the Czech Dermatovenerological Society of the Czech Medical Society of Jan Evangelista Purkyně (Mladí dermatovenerologové
• Česká dermatovenerologická společnost - Česká lékařská společnost Jana Evangelisty Purkyně)
• Czech Academy of Dermatovenereology (Česká akademie dermatovenerologie)

The Second Guangdong Young and Middle-aged Physician

Vice Chairman of the Evidence-Based Medicine Committee of the Sino-German Medical Association

Member of the Radioimmunology Working Committee of the Chinese Tumor Radiotherapy Alliance (CRTOG)

Standing Member of the Radioimmunology Youth Committee of the Chinese Tumor Radiotherapy Alliance (CRTOG)

Member and Secretary of the Nasopharyngeal Carcinoma Professional Committee of the Guangdong Anti-Cancer Association

Vice Chairman of the Youth Committee of the Nasopharyngeal Carcinoma Professional Committee of the Guangdong Anti-Cancer Association

Standing Member of the Rare Tumor Branch of the Guangdong Precision Medicine Application Association

Executive Director of the Guangdong Medical Consumables Management Association

Chairman of the Clinical Innovation and Transformation Committee of the Guangdong Medical Consumables Management Association

Prof. DSc Irena Kostova graduated from Mendeleev University in Moscow with the highest grade. Appointed as a research scientist at the Research Center of the Ministry of Environment, and since 1994 she has been teaching “General and Inorganic Chemistry” at MU-Sofia. Since 2013 she is a full professor at Chemistry Department. Defended her PhD thesis “Synthesis and characterization of metal complex compounds of coumarin derivatives” and DSc thesis “New complex compounds of lanthanides(III) with biologically active ligands”. Graduated her second specialization “Theoretical bases of medical chemistry” at Medical University-Sofia. Her research interests include the developmental work in theoretical and coordination chemistry, vibrational spectroscopy, pharmacological investigations on biologically active compounds etc. Author of 150 publications with impact factor, 3 textbooks, 4 education book materials, 4 monographs with around 6000 citations in indexed journals in J. Citation Reports of Clarivate, Scopus of Elsevier, Web of Science of Clarivate, Google Scholar. She is a lecturer at renowned universities in India, Germany, Austria, Italy, Romania, Spain, Slovakia etc. Member of the organizing committees of over 20 international conferences. She is an Editor of 6 prestigious international scientific journals, a member of the Editorial Boards of over 25 international scientific journals and a reviewer for numerous high-ranking journals and international projects. She has been a member of the Scientific Experts Panel of Medical Sciences and Chemical Sciences at the National Science Fund of the Ministry of Education and Science. She has created and maintains collaborations with a number of European universities in the framework of joint research projects and European programs. She has been a principal investigator of several national and international projects. Prof. Irena Kostova is one of the World’s Top 1% of scientists according to Elsevier’s and Stanford University’s ranking of scientists with the greatest contribution to the development of modern science.

PD Dr. med. Philipp Kron is a Transplant- and HPB- surgeon and working as a consultant surgeon at the University Hospital Zurich, Switzerland. His main research interests are pre- clinical and clinical projects, focusing on different organ perfusion approaches. The main aims of his work are to further increase utilisation rates in organ transplantation by understanding the mechanism of different perfusion modalities and making outcomes safer for our patients.

Important academic research results and contributions:

Nuclear factor κB (NF-κB) is a multifunctional nuclear transcription factor that plays a core regulatory role in the physiological and pathological processes of the body. A large number of epidemiological and experimental studies have shown that the NF-κB signaling pathway is highly and continuously activated in a variety of tumors and is involved in many important processes of tumor development, such as anti-apoptosis, pro-proliferation, angiogenesis, invasion and metastasis. Therefore, taking the regulatory mechanism of the tumor NF-κB signaling pathway as the research entry point, finding and identifying the key regulatory nodes at different levels of the pathway not only adds new theoretical basis for tumor development, but also provides important target sites for the development of tumor therapeutic drugs.

Research team: ⑴. Proved that miR-182 and miR-486 can simultaneously downregulate multiple NF-κB pathway inhibitors, elucidating a new mechanism for the persistent activation of NF-κB in tumors (J Clin Invest; Cell Res); ⑵. Found that miR-30e* can inhibit the translation of IκB-α protein, revealing a new mechanism for the negative feedback loss of control of the tumor NF-κB pathway (J Clin Invest); ⑶. Clarified the new function of the lipid raft protein FLOT-1 in transmitting extracellular inflammatory signals to the NF-κB pathway, adding new content to the regulation of the membrane receptor proximal NF-κB pathway (Gastroenterology).

Yang Li, PhD, Deputy director of LIV. Talented researcher awarded a Marie Skłodowska-Curie Actions fellowship, he graduated from Salzburg University in Austria with a PhD degree. He has successively engaged in research on nano immunology and cancer immunology in the European National Academy of Sciences, the Kansas Nanotechnology Research and Development Center and the University of Colorado in the United States. He is now the deputy director of Laboratory of Inflammation and Vaccines (LIV) of the Institute of Biomedicine and Biotechnology, SIAT, Chinese Academy of Sciences, presided over two NSFC programs, international cooperation programs of the Academy of Sciences, participated in the R01 research program of the United States, etc., and published more than 30 papers in international well-known journals including Nature Nanotechnology, Biomaterials, Nature Communications, Nanochemistry; He was awarded the first prize of natural science in Hebei Province. Member of Italian Society of Immunology and Clinical Immunology, The Biophysical Society of China (BSC) and The Chinese Society of Toxicology (CST), guest editor of Frontiers in Immunology, reviewer of Advanced Science, ACS Nano, Small and other specialized scientific journals.

From 2011 to 2013, as the project leader, he undertook a number of research projects, including the Ministry of Science and Technology's international cooperation projects, the National Natural Science Foundation of China's general projects and youth funds, the Ministry of Education's doctoral program funds, the Jilin Provincial Science and Technology Department's natural science foundation general projects and youth funds; published more than 20 SCI-indexed papers, participated in the editing of one academic book, won one national invention patent and one second prize of Jilin Province Natural Science Academic Achievement Award.

Junliang Liu underwent his Radiation Oncology Residency in University of Manitoba, Canada from 2000 to 2005. Since July 2005, he has been an attending Radiation Oncologist working at CancerCare Manitoba, Canada. He was the Radiation Oncology Residency Program Director from 2006 to 2012. He graduated from West China University of Medical Sciences (now is the Medical School Sichuan University), China in 1983 and pursued a Master’s Degree in Pediatrics from 1983 to 1986 in the same medical school. He was a Pediatrician working at Sichuan Provincial People’s Hospital, China from 1986 to 1991. He was a Guest Researcher supervised by Professor Hans Wigzell at the Department of Immunology, Karolinska Institute, Sweden, from 1991 to 1994. He earned a PhD in Immunology from La Trobe University, Melbourne, Australia in 1997, and conducted Post-Doctoral Research in Immunology at University of Alberta, Canada, from 1997 to 2000, before his residency training in Radiation Oncology. His publications included the ones in the prestigious journals of Nature Medicine and Proceedings of the National Academy of Sciences of the United States of America (PNAS). His current research interest is the treatment outcomes of gastrointestinal malignancies, breast cancer, and metastatic cancer.

Doctor of Oncology, Associate Chief Physician, Associate Professor, Master Supervisor. Jointly trained doctor and visiting scholar at the University of Texas MD Anderson Cancer Center. Has rich clinical experience in the comprehensive treatment of various malignant tumors. Currently serving as Standing Committee Member and Secretary of the Expert Committee of Evidence-Based Medicine of the Sino-German Medical Association, Young Director of the Chinese Anti-Cancer Association, Standing Committee Member of the MDT Expert Committee of Adverse Reactions of Immunotherapy of the Hubei Medical Biological Immunology Society, Member of the Young Expert Committee of the Hubei Clinical Oncology Society, and Member of the Young Committee of the Oncology Branch of the Wuhan Medical Association. Won the Hubei May Fourth Youth Medal, Wuhan "Hanyang" Youth Talent, the Fourth Chinese Clinical Oncology Society "35 under 35" Outstanding Young Oncologist, Hubei Science and Technology Progress First Prize and other honors. Published more than 30 SCI papers in international authoritative journals such as "Lancet Oncology" as the first author or corresponding author (including co-author), including 9 papers with IF>10 points, and presided over 5 national and provincial and municipal projects such as the National Natural Science Foundation.

Doctor of Medicinal Chemistry, professor, doctoral supervisor. In 2008, he went to the research group of Professor Ronald Gust of the School of Pharmacy of the Free University of Berlin, Germany to study for a doctorate in medicinal chemistry. After graduating with a doctorate in 2012, he joined the research group of Professor Jun O. Liu of the Johns Hopkins University School of Medicine in the United States to conduct postdoctoral research. In 2017, he worked at Nanjing University of Chinese Medicine. He was successively selected as a distinguished professor of Jiangsu, the spokesperson of the rhodium element in the "Periodic Table of Chinese Young Chemists" of the Chinese Chemical Society, a high-level talent training target of the "Six Talent Peaks" of Jiangsu Province, a core member of the "Double Innovation Team" of Jiangsu Province, a training target of the "333 Talent Project" of Jiangsu Province (third level), a young top talent of the National "Ten Thousand Talents Plan", and an excellent doctoral dissertation supervisor in Jiangsu Province in 2022.

Mainly engaged in the design, synthesis and anti-tumor activity research of new thioredoxin reductase inhibitors, immunogenic cell death inducers and selective estrogen receptor downregulators. He presided over many projects such as the National Natural Science Foundation. As the first or corresponding author, he has published more than 40 papers in journals such as J. Med. Chem. (11 papers), Eur. J. Med. Chem. (8 papers), Chem. Soc. Rev. (2 papers), Coord. Chem. Rev. (3 papers), Med. Res. Rev., Redox Biol. (2 papers), Pharmacol. Res. (2 papers), Chin. Chem. Lett., Drug Discov. Today, Chem. Eur. J., etc. He has recently applied for 8 national invention patents and 4 of them have been authorized. He is currently a reviewer for academic journals such as Med. Res. Rev. and J. Med. Chem.; an editorial board member of Cancer Plus; and a young editorial board member of Chin. Chem. Lett. and Acta Mater. Med. He has served as a guest editor of special issues of Pharmaceutics and Front. Chem. magazines, and participated in the translation of "Successful Drug Development III". 。

Dr. Miyamoto is a surgical pathologist and the Director of Genitourinary Pathology. He is trained and has worked both as a urologist and as a pathologist. He has also been engaged in research mainly involving bladder and prostate cancers.

• FEBS bursary for attending the 34th FEBS Congress in Prague, Czech Republic
• FEBS bursary for attending the 35th FEBS Congress in Gothenburg, Sweden
• EACR Travel Fellowship
• FEBS Collaborative Experimental Scholarships for Central & Eastern Europe
• Croatian Science Foundation’s Fellowship for Doctoral Students (project number 03.01/214)

Am an Associate Research Scientist at Yale Center for Genome Analysis with a Masters in Computer Science and a Ph.D. from Georgia State University, Atlanta. My dissertation was focused on big data (next-generation sequencing, microarrays, X-ray crystallography etc.) analysis with machine learning techniques (Neural networks, SVM’s, Restricted boltzmann machines, Clustering algorithms etc.). If you share similar interests feel free to contact. You can browse some of my recent machine learning applications on GitHub in projects. The detailed list of credentials can be found at: Linkedin, NCBI Bibliography or Google Scholar.

Qian Haili is a researcher at the State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, and a doctoral supervisor at Peking Union Medical College. From 1994 to 2002, he received a bachelor's degree in clinical medicine and a master's degree in pathology and pathophysiology from North China Coal Medical College. In 2005, he graduated from Peking Union Medical College with a doctorate degree. In the same year, he was hired to work at the State Key Laboratory of Molecular Oncology, Cancer Institute, Cancer Hospital, Chinese Academy of Medical Sciences. From 2008 to 2009, he conducted postdoctoral research at the University of North Carolina at Chapel Hill. He is currently the deputy editor-in-chief of Military Medicine Research, an editorial board member of the PLA Medical Journal, Cancer Progress, etc., a youth director of the Chinese Anti-Cancer Association, a standing member of the Etiology Committee of the Chinese Anti-Cancer Association, a vice chairman of the Molecular Oncology and Immunotherapy Committee of the Chinese Research Society, and a standing member of the Tumor Immunotherapy Committee of the Beijing Breast Disease Prevention and Treatment Society. He has undertaken two 973 and 863 key projects, seven National Natural Science Foundation projects and many other provincial and ministerial projects, published more than 50 papers in journals such as Nature Communications, Leukemia, Oncogene, Molecular Oncology, and obtained four authorized patents and two provincial and ministerial awards. He mainly studies the mechanisms and new strategies of tumor metastasis and treatment.

Author of over 70 articles in journals indexed on Pubmed:

Main research areas:

- Peri-prosthetic infections

- Sarcomas of bone and soft tissue

- Biological and prosthetic reconstructions

https://pubmed.ncbi.nlm.nih.gov/?term=sambri+a&sort=date

Participation in numerous national and international congresses as a speaker.

Post-doctoral Research Fellow: Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN
Ph.D., Cancer Biology: Chittaranjan National Cancer Institute (Jadavpur University), India
M.S., Applied Clinical and Preclinical Research (MACPR): The Ohio State University, Columbus, OH
M.S., Zoology: Visva Bharati University, India 

Dr. Heloisa Sobreiro Selistre-de-Araujo is a professor at the Universidade Federal de São Carlos, Brazil. Her research focuses on molecular biology, cancer biology, and the biochemical characterization of proteins with potential therapeutic applications. She has authored numerous scientific publications and is actively involved in academic and collaborative research projects in the field of oncology.

Highly accomplished and driven professional with over 7 years of experience in Drug Discovery and Development. Leveraging a rich 5-year background in non-clinical drug discovery, I have transitioned to clinical development in the last 2 years. I have deep familiarity with AI-driven non-clinical and clinical development workflows from working at Recursion (a leading Tech-Bio company utilizing LLM and AI in Drug Discovery). I excel in interdisciplinary collaboration and strategic program leadership. Currently serving as a Lead Clinical Scientist for both rare disease (FAP) and oncology clinical trials, I am adept at protocol management, medical monitoring, and safety oversight, with a strong focus on advancing innovative oncology therapies.

Dr. John Spiliotis is a distinguished surgical oncologist affiliated with both the European Interbalkan Medical Center in Thessaloniki and Athens Medical Center in Athens, Greece. He has extensive clinical experience in oncology surgery and has contributed significantly to cancer treatment strategies, particularly in gastrointestinal and hepatobiliary cancers. Dr. Spiliotis is actively involved in academic research and has published widely in international medical journals.

Specialized in Obstetrics and Gynecology at the University Medical School of Bari. Professional Training in Gynecological Laparoscopy at the Center for Advanced Pelvic Surgery and National Center for Endometriosis (European Gynecologic Endoscopic School), Malzoni Medical Center, Avellino, Italy, directed by Dr Mario Malzoni. National Authorirization as Associate Professor in Obstetrics and Gynecology.

Dr. Stelvio Tonello is a researcher at the Università del Piemonte Orientale, affiliated with both the Department of Translational Medicine and the Department for Sustainable Development and Ecological Transition. His academic work bridges biomedical innovation with sustainability, with research interests focusing on translational approaches to human health, environmental impact on disease development, and interdisciplinary strategies for ecological resilience. Dr. Tonello contributes to various scientific collaborations at the intersection of medicine and sustainability.

Currently, he holds a position of Very High Professionalism for the implementation of the Peritoneal Tumor Surgery Program, General, Emergency and Oncological Surgery Unit, University Hospital Policlinico di Modena, as well as being coordinator of the Peritoneal Tumor Oncoteam of the Italian Society of Oncological Surgery (SICO) from 2017 to 2023.

Member of scientific societies such as SICO, ESSO (European Society of Surgical Oncology) and the Peritoneal Surface Malignancies Oncology Group International. He collaborated in the drafting of the AIOM Guidelines for Peritoneal Tumors.

He is author/co-author of over 60 national and international scientific publications, 8 book chapters and boasts the participation in over 150 scientific congresses in Italy and abroad, as a speaker, but also as session chairman/moderator.

Dr. Maria Rosaria Valerio is a researcher at the School of Medicine and Surgery, University of Palermo, Italy. Her academic interests focus on medical and clinical sciences, with particular attention to disease mechanisms and therapeutic approaches. She is actively engaged in interdisciplinary research and contributes to advancing healthcare knowledge through scientific publications and collaborations.

National School Tuberculosis Prevention and Control Expert

Young Member of the Microbiology and Immunology Branch of the Chinese Medical Association

Member of the Medical Microbiology and Immunology Society of the Chinese Society of Microbiology

Director of the Jilin Province Zoonoses Society

In 2009, he obtained his doctorate in medicine under the tutelage of Academician Chen Xiaoping. He went to the United States to study and work for more than two years. He has been engaged in surgical clinical work for 20 years, mainly engaged in clinical and basic research related to general surgical diseases such as liver, gallbladder, pancreas and spleen. He has participated in the diagnosis and treatment of various general surgical critical diseases and rescue, and the diagnosis and surgical treatment of various complex benign and malignant diseases of the liver, gallbladder, pancreas and spleen. He presided over one National Natural Science Foundation Youth Fund Project and one National Natural Science Foundation General Fund Project, and participated in five National Natural Science Foundation General Fund Projects. He has published nearly 60 papers in professional journals at home and abroad, including more than 20 SCI articles. He serves as a special reviewer for the Journal of Clinical Surgery and a reviewer for more than ten authoritative medical journals abroad.

Dr. Dejian Zhao is a researcher at the Department of Genetics, Yale School of Medicine. His work focuses on genetic regulation, molecular biology, and translational genomics. Dr. Zhao has contributed to advancing our understanding of gene expression and its role in human diseases, with a particular interest in cancer genetics and developmental biology.

He has been engaged in clinical diagnosis and treatment of tumors for 25 years. He is currently the chief physician, professor, doctoral supervisor, and deputy director of the Science and Technology Department of the First Affiliated Hospital of Soochow University. In 2020, he was awarded the title of "National Famous Doctor" by the People's Daily. In 2017, he visited and studied at the Cancer Center of the Affiliated Hospital of the University of Michigan Medical School for one year. He has won the Jiangsu Province Six Peak Talent Award, the Suzhou Health Key Talent Award, the Doctoral Tutor of the First Affiliated Hospital of Soochow University, and the Second Prize for Excellent Academic Papers in Natural Sciences in Suzhou City. He has obtained 1 invention patent and written 4 academic monographs. He is mainly good at the diagnosis, chemotherapy, immunity, biological targeted therapy and formulation of comprehensive treatment strategies for solid tumors such as lung cancer, esophageal cancer, gastrointestinal tumors, breast cancer, gynecological tumors, head and neck tumors, and soft tissue sarcomas. He serves as a member of the CSCO (Chinese Society of Clinical Oncology) Liver Cancer Expert Committee, a member of the CSCO Tumor Nutrition Therapy Expert Committee, a member of the CSCO Youth Expert Committee, a CSCO Clinical Oncology Research Fund Reviewer, a standing member of the Hepatobiliary and Pancreatic MDT Professional Committee of the Chinese Branch of the International Hepatobiliary and Pancreatic Association, a standing member of the Lung Cancer Professional Committee of the Jiangsu Anti-Cancer Association, and a member of the Translational Medicine Branch of the Jiangsu Immunology Society.

Professor Zhu Pingping has studied the microenvironmental regulation and epigenetic regulation of long-term stem cells (adult stem cells and tumor stem cells), identified multiple stemness regulatory factors and regulatory pathways of tumor stem cells and intestinal stem cells, and discovered a new model of immune microenvironment regulation of intestinal stem cells. Professor Zhu Pingping has successively presided over the China Association for Science and Technology Young Talent Support Project, the Postdoctoral Innovation Talent Support Program, the National Natural Science Foundation of China General Project, and the Excellent Youth Project. He has published more than ten papers as the first author or general author in journals such as Nat Immunol, Nat Cell Biol, Nat Struct Mol Biol, J Clin Invest and Nat Commun, and has published more than 30 SCI articles in total, with a total impact factor of more than 300 and a citation rate of more than 1,000 times in two years. He has won the Special Award of the President of the Chinese Academy of Sciences and the First Prize of Beijing Science and Technology Progress.

Dr. Beatrice Trabalza Marinucci is a researcher and clinician at the Department of General and Specialized Surgery, Sant'Andrea Hospital, affiliated with Sapienza University of Rome. Her work focuses on surgical oncology and translational research, with particular interest in improving treatment outcomes for cancer patients. She is actively involved in clinical studies and contributes to academic teaching and scientific publications in the field of surgery and oncology.

Dr. Giovanni Pecorella is a specialist in obstetrics and gynecology at the Veris delli Ponti Hospital in Scorrano, Italy. He is also actively involved in clinical research through CERICSAL, focusing on women's health, reproductive medicine, and gynecologic oncology. With years of clinical and academic experience, Dr. Pecorella contributes to advancing evidence-based practices and improving patient outcomes in gynecological care.

He is currently committed to studying the regulatory effects of metal polyphenol coordination nanosystems in the treatment of tumors and other diseases. He has obtained the National Natural Science Foundation Youth Fund, the National Overseas Talent Introduction Project, the Shanxi Basic Research Plan (Free Exploration Category) Youth Fund, the Shanxi Traditional Chinese Medicine Research Project (Reserve) and other projects, and participated in many general projects and the Macau Science and Technology Development Fund. So far, he has published more than 30 SCI papers, and the cumulative impact factor of the first author and co-author articles has reached 180, including 1 article selected as the magazine cover article and ESI highly cited paper. He wrote the Metal Coordination Nanomedicine chapter in the book Micro/Nano Technologies. Nanomedicine, and conducted an in-depth summary and analysis of the various nanomaterials formed by metal polyphenol coordination and prospects. The research results won the international SLB/JLB Trainee Outstanding Research Award in 2021.

I am mainly engaged in the diagnosis and treatment of hematological malignancies, especially molecular targeted therapy and cellular immunotherapy for lymphoma. Fortunately, during my 10-year medical career, lymphoma diagnosis and treatment technology has been booming. New technologies and methods have emerged in an endless stream, solving the suffering of patients while also broadening the horizons of doctors. Taking this opportunity, on the one hand, I participated in various clinical studies related to lymphoma, summarized clinical experience, published several articles, and helped later generations avoid pitfalls. On the other hand, I discovered problems in clinical practice, conducted in-depth research, and came up with various wonderful ideas, which enabled me to apply for several funds. I am looking for like-minded classmates to jointly discover more stories behind the disease in research, and ultimately contribute my own efforts to conquer the disease.